Xenetic Biosciences | 8-K: FY2025 Q3 Revenue: USD 1 M

Revenue: As of FY2025 Q3, the actual value is USD 1 M.

Financial Metrics by Segment

Net Loss

• Net loss for the quarter ended September 30, 2025 was approximately $0.5 million.

Research & Development Expenses

• Research & development expenses for the three months ended September 30, 2025 increased by approximately $0.4 million, or 105.6%, to approximately $0.8 million from $0.4 million in the comparable quarter in 2024. This increase was primarily due to increased manufacturing development efforts and pre-clinical research as well as increased consulting costs.

General and Administrative Expenses

• General and administrative expenses for the three months ended September 30, 2025 increased by approximately $0.1 million, or 9.3%, to approximately $0.8 million from approximately $0.7 million in the comparable quarter in 2024. This increase was primarily due to increased legal costs in connection with the Company’s strategic review process.

Revenue

• Revenue for the three months ended September 30, 2025 increased by approximately $0.4 million, or 67.2%, to approximately $1.0 million from approximately $0.6 million for the three months ended September 30, 2024. This increase represented an increase in royalty revenue related to Xenetic’s sublicense agreement with Takeda Pharmaceuticals Co. Ltd. as compared to the same period in 2024 primarily due to royalties recognized from certain countries during the third quarter of 2025 compared to the same period in 2024.

Cash Position

• The Company ended the quarter with approximately $4.1 million cash. Subsequent to quarter end, the Company closed an underwritten offering for net proceeds of approximately $3.9 million.

Outlook / Guidance

• Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. The company plans to build on proof-of-concept success and advance to mechanism-of-action and translational studies in preparation for a Phase 1 clinical trial. The report includes forward-looking statements indicating that the company’s future activities, performance, achievements, or results may differ materially from those anticipated due to various risks and uncertainties, including market factors, economic conditions, public health issues, geopolitical events, competitive product development, regulatory processes, manufacturing issues, patent positions, litigation, and shareholder activism.